Rituximab therapy in primary Sjögren's syndrome

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 701-705

  Alcântara, Cristina ^a   Gomes, Maria João ^b   Ferreira, Carlos ^b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

B cell hyperactivity; Rituximab; Sj gren's syndrome; Sj gren associated lymphoma

Indexed keywords

B CELL ACTIVATING FACTOR; BELIMUMAB; CHIMERIC ANTIBODY; CLEMASTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC RECEPTOR; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; B CELL LYMPHOMA; B LYMPHOCYTE; CELL ACTIVATION; CELL CLONE; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; DISEASE COURSE; FEVER; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PURPURA; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 69949144269     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04639.x     Document Type: Conference Paper

References (20)

1. Ramos-Casals, M. & P. Brito-Zerón. 2007. Emerging biological therapies in primary Sjögren's syndrome. Rheumatology 46: 1389-1396.
2. Skopouli, F.N., U. Dafni, J.P. Ioannidis & H.M. Mout-sopoulos. 2000. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin. Arthritis Rheum. 29: 296-304.
3. Looney, R.J. 2007. Will targeting B cells be the answer for Sjögren's syndrome? Arthritis Rheum. 56: 1371-1377.
4. Stadanlick, J.E. & P.M. Cancro. 2008. BAFF and the plasticity of peripheral B cell tolerance. Curr. Opin. Immunol. 20: 158-161.
5. Jonsson, M.V., P. Szodoray, S. Jellestad, et al. 2005. Association between circulating levels of the novel TNF family members APRIL and BAFF and lym-phoid organization in primar Sjögren's syndrome. J. Clin. Immunol. 25: 189-201.
6. Theander, E., G. Henriksson, O. Ljungberg, et al. 2006. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis. 65: 796-803.
7. Ekström Smedby, K., C.M. Vajdic, M. Falster et al. 2008. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038.
8. Mournier, N., J. Briere, C. Gisselbrecht, et al. 2003. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284.
9. Arkfeld, D.G. 2008. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol. Int. 28: 205-215.
10. Seror, R., C. Sordet, L. Guillevin, et al. 2007. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann. Rheum. Dis. 66: 351-357.
11. Devauchelle-Pensec, V., Y. Pennec, J. Morvan, et al. 2007. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57: 310-317.
12. Gottenberg, J.E., L. Guillevin, O. Lambotte, et al. 2005. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64: 913-920.
13. Pijpe, J., G.W. van Imhoff, F.K. Spijkervet, et al. 2005. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52: 2740-2750.
14. Dass, S., S. Bowman, E.M. Vital, et al. 2008. Reduction of fatigue in Sjögren syndrome with ritux-imab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67: 1541-1544.
15. Carbone, J., R. Perez-Fernandez, A. Muñoz, et al. 2008. Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjo-gren's syndrome-associated B-cell non-Hodgkin's lymphoma. Clinic. Rev. Allerg. Immunol. 34: 80-84.
16. Voulgarelis, M., S. Giannouli, A.G. Tzioufas & H.M. Moutsopoulos. 2006. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, dox-orubicin, vincristine, prednisone). Ann. Rheum. Dis. 65: 1033-1037.
17. Voulgarelis, M., S. Giannouli, D. Anagnostou & A.G. Tzioufas. 2004. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/ vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology 43: 1050-1053.
18. Smolen, J.S., E.C. Keystone, P. Emery, et al. 2007. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66: 143-150.
19. Boren, E.J., G.S. Cheema, S.M. Naguwa, et al. 2008. The emergence of progressive multifocal leu-coencphalopathy (PML) in rheumatic diseases. J. A u-toimmun. 30: 90-98.
20. Dörner, T. & G.R. Burmester. 2008. New approachs of B cell directed therapy: beyond rituximab. Curr. Opin. Rheumatol. 20: 263-268.